SG170749A1 - Anti-ilt7 antibody - Google Patents

Anti-ilt7 antibody

Info

Publication number
SG170749A1
SG170749A1 SG201102016-1A SG2011020161A SG170749A1 SG 170749 A1 SG170749 A1 SG 170749A1 SG 2011020161 A SG2011020161 A SG 2011020161A SG 170749 A1 SG170749 A1 SG 170749A1
Authority
SG
Singapore
Prior art keywords
ilt7
ipc
antibody
activity
ifna
Prior art date
Application number
SG201102016-1A
Other languages
English (en)
Inventor
Yumiko Kamogawa
Minkwon Cho
Naoko Arai
Koji Ishida
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of SG170749A1 publication Critical patent/SG170749A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
SG201102016-1A 2005-12-20 2006-12-20 Anti-ilt7 antibody SG170749A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20

Publications (1)

Publication Number Publication Date
SG170749A1 true SG170749A1 (en) 2011-05-30

Family

ID=38188642

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201602095PA SG10201602095PA (en) 2005-12-20 2006-12-20 Anti-Ilt7 Antibody
SG201102016-1A SG170749A1 (en) 2005-12-20 2006-12-20 Anti-ilt7 antibody

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201602095PA SG10201602095PA (en) 2005-12-20 2006-12-20 Anti-Ilt7 Antibody

Country Status (29)

Country Link
US (6) US8084585B2 (fr)
EP (4) EP2532681B1 (fr)
JP (2) JP5020828B2 (fr)
KR (3) KR101526934B1 (fr)
CN (4) CN110776566A (fr)
AU (1) AU2006328470B2 (fr)
BR (1) BRPI0620141B1 (fr)
CA (2) CA2994756C (fr)
CY (3) CY1114227T1 (fr)
DK (3) DK1964852T3 (fr)
ES (3) ES2526079T3 (fr)
HK (4) HK1124347A1 (fr)
HR (2) HRP20130494T1 (fr)
HU (1) HUE039865T2 (fr)
IL (1) IL192266A (fr)
LT (1) LT2913343T (fr)
ME (1) ME02111B (fr)
MX (1) MX2008007682A (fr)
NZ (3) NZ616992A (fr)
PL (3) PL2913343T3 (fr)
PT (3) PT2913343T (fr)
RS (2) RS53752B1 (fr)
RU (2) RU2456298C2 (fr)
SG (2) SG10201602095PA (fr)
SI (3) SI1964852T1 (fr)
TR (1) TR201816574T4 (fr)
UA (1) UA97946C2 (fr)
WO (1) WO2007072866A1 (fr)
ZA (1) ZA200805850B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
AU2010319531A1 (en) * 2009-11-10 2012-05-24 Amgen Inc. Anti-c-MPL antibodies
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
NZ724971A (en) 2010-02-24 2019-06-28 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
EP3085387A1 (fr) 2010-04-26 2016-10-26 Abraxis BioScience, LLC Anticorps se liant aux sparc et leurs utilisations
KR20230013283A (ko) 2011-04-01 2023-01-26 이뮤노젠 아이엔씨 Folr1 암 치료의 효능을 증가시키기 위한 방법
CA2867902C (fr) 2012-03-20 2023-09-26 Biogen Idec Ma Inc. Anticorps neutralisant le virus jcv
US9567391B2 (en) 2012-03-20 2017-02-14 Biogen Ma Inc. JCV neutralizing antibodies
WO2014022758A1 (fr) * 2012-08-03 2014-02-06 Dana-Farber Cancer Institute, Inc. Anticorps de liaison double à agent unique anti-pd-l1 et pd-l2 et procédés d'utilisation
PL2890717T3 (pl) 2012-08-31 2020-08-10 Immunogen, Inc. Testy i zestawy diagnostyczne do wykrywania receptora folianu
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
WO2015051159A1 (fr) * 2013-10-02 2015-04-09 The Rockefeller University Anticorps de protofibrilles amyloïdes et leurs procédés d'utilisation
CN105829534B (zh) * 2013-12-24 2021-08-03 安斯泰来制药株式会社 抗人bdca-2抗体
SI3218005T1 (sl) 2014-11-12 2023-06-30 Seagen Inc. Z glikanom delujoče spojine, in postopki uporabe
DK3270965T3 (da) * 2015-03-18 2020-06-08 Seattle Genetics Inc Cd48-antistoffer og konjugater deraf
BR112017027254A2 (pt) * 2015-06-29 2019-05-14 Immunogen, Inc. anticorpos anti-cd123 e conjugados e derivados dos mesmos
MA42844A (fr) 2015-09-17 2018-07-25 Immunogen Inc Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1
CA3002097A1 (fr) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Composes interagissant avec le glycane et methodes d'utilisation
WO2017087800A1 (fr) * 2015-11-19 2017-05-26 Abbvie Stemcentrx Llc Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
CN109069211B (zh) 2016-01-26 2022-04-29 网络牙科(美国)公司 自动牙科治疗系统
US20190031780A1 (en) * 2016-01-27 2019-01-31 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
US10906987B2 (en) * 2016-03-01 2021-02-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (PVR)
KR102632796B1 (ko) * 2016-03-10 2024-02-02 비엘라 바이오, 인크. Ilt7 결합 분자 및 이의 사용 방법
MX2018012176A (es) 2016-04-04 2019-02-07 Bioverativ Usa Inc Anticuerpos anti-factor bb del complemento y usos de estos.
MX2019010202A (es) 2017-03-03 2019-10-02 Seattle Genetics Inc Compuestos que interactuan con glicano y metodos de uso.
CA3073733A1 (fr) 2017-08-30 2019-03-07 Phanes Therapeutics, Inc. Anticorps anti-lag-3 et leurs utilisations
EP3694874A1 (fr) 2017-10-11 2020-08-19 Bioverativ USA Inc. Procédés permettant d'induire une activité de complément
MA50900A (fr) * 2017-11-17 2020-09-23 Merck Sharp & Dohme Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations
US11396538B2 (en) 2017-12-20 2022-07-26 Radimmune Therapeutics, Inc. Antibodies to centrin-1, methods of making, and uses thereof
US11655295B2 (en) * 2018-01-18 2023-05-23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-LAG-3 antibody and use thereof
TW202003576A (zh) * 2018-05-10 2020-01-16 美商艾博視訊有限公司 活化cd40之單株抗體及其用途
CA3159511A1 (fr) * 2019-12-06 2021-06-10 William Rees Methodes de traitement a l'aide de proteines de liaison a l'ilt7
EP4139350A4 (fr) 2020-04-20 2024-04-24 Genzyme Corp Anticorps humanisés anti-facteur bb du complément et leurs utilisations
AU2022270101A1 (en) 2021-05-04 2023-10-05 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
TW202404640A (zh) 2022-07-27 2024-02-01 美商維埃拉生物股份有限公司 包含免疫球蛋白樣轉錄本７（ｉｌｔ７）結合蛋白之調配物
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
DK1156823T3 (da) * 1999-02-12 2009-01-19 Scripps Research Inst Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
ATE442444T1 (de) * 2001-10-13 2009-09-15 Asterion Ltd Glykosylphosphatidylinositolhaltige polypeptide
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
JP4498136B2 (ja) 2002-08-01 2010-07-07 Ｓｂｉバイオテック株式会社 マウスインターフェロン産生細胞の検出方法
WO2004023973A2 (fr) * 2002-09-12 2004-03-25 Incyte Corporation Molecules utilisees a des fins diagnostiques et therapeutiques
AU2004271192B2 (en) 2003-09-03 2011-11-17 Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Also Published As

Publication number Publication date
DK2532681T3 (en) 2015-01-05
PL2913343T3 (pl) 2019-03-29
CY1116031T1 (el) 2017-01-25
US20160130343A1 (en) 2016-05-12
EP2913343B1 (fr) 2018-08-08
CY1121294T1 (el) 2020-05-29
RS53752B1 (en) 2015-06-30
RU2012112046A (ru) 2013-10-10
ME02111B (me) 2015-10-20
HK1179638A1 (en) 2013-10-04
UA97946C2 (ru) 2012-04-10
ES2416716T3 (es) 2013-08-02
ES2526079T3 (es) 2015-01-05
MX2008007682A (es) 2008-10-23
SI1964852T1 (sl) 2013-09-30
EP1964852A4 (fr) 2010-02-24
CA2634116A1 (fr) 2007-06-28
EP1964852A1 (fr) 2008-09-03
EP2532681B1 (fr) 2014-10-01
US20090280128A1 (en) 2009-11-12
HK1218126A1 (zh) 2017-02-03
HRP20141226T1 (hr) 2015-02-27
AU2006328470A1 (en) 2007-06-28
LT2913343T (lt) 2018-11-26
JP2012143232A (ja) 2012-08-02
BRPI0620141B1 (pt) 2024-04-30
RU2008129715A (ru) 2010-01-27
PT2532681E (pt) 2014-12-23
EP2532681A1 (fr) 2012-12-12
KR20080090430A (ko) 2008-10-08
TR201816574T4 (tr) 2018-11-21
KR101526934B1 (ko) 2015-06-26
KR20150031485A (ko) 2015-03-24
PL2532681T3 (pl) 2015-03-31
US20120135003A1 (en) 2012-05-31
PL1964852T3 (pl) 2013-09-30
JP5020828B2 (ja) 2012-09-05
KR101624587B1 (ko) 2016-05-26
NZ599683A (en) 2013-11-29
HUE039865T2 (hu) 2019-02-28
US8084585B2 (en) 2011-12-27
HRP20130494T1 (en) 2013-08-31
US8470992B2 (en) 2013-06-25
SG10201602095PA (en) 2016-05-30
CN101379089A (zh) 2009-03-04
EP1964852B1 (fr) 2013-04-17
KR20140053232A (ko) 2014-05-07
DK1964852T3 (da) 2013-07-08
EP2913343A1 (fr) 2015-09-02
KR101585532B1 (ko) 2016-01-14
WO2007072866A1 (fr) 2007-06-28
CN101379089B (zh) 2013-08-07
JP5420688B2 (ja) 2014-02-19
US20130259872A1 (en) 2013-10-03
RU2456298C2 (ru) 2012-07-20
NZ569910A (en) 2012-06-29
IL192266A (en) 2014-09-30
RU2599450C2 (ru) 2016-10-10
US20170204179A1 (en) 2017-07-20
RS52860B (en) 2013-12-31
US20200339682A1 (en) 2020-10-29
EP3441403A1 (fr) 2019-02-13
CN105111311A (zh) 2015-12-02
JPWO2007072866A1 (ja) 2009-06-04
CN110776566A (zh) 2020-02-11
DK2913343T3 (en) 2018-11-26
IL192266A0 (en) 2008-12-29
CA2994756C (fr) 2020-10-27
CA2634116C (fr) 2018-03-27
PT2913343T (pt) 2018-11-21
CN103360492A (zh) 2013-10-23
NZ616992A (en) 2015-07-31
SI2532681T1 (sl) 2015-03-31
CN105111311B (zh) 2019-10-18
SI2913343T1 (sl) 2019-01-31
CA2994756A1 (fr) 2007-06-28
HK1214603A1 (zh) 2016-07-29
AU2006328470B2 (en) 2012-08-16
AU2006328470A2 (en) 2008-10-09
ZA200805850B (en) 2009-04-29
PT1964852E (pt) 2013-07-10
CY1114227T1 (el) 2016-08-31
BRPI0620141A2 (pt) 2011-11-01
ES2699428T3 (es) 2019-02-11
HK1124347A1 (en) 2009-07-10

Similar Documents

Publication Publication Date Title
SG170749A1 (en) Anti-ilt7 antibody
EA200801427A1 (ru) Молекулы антитела со специфической активностью в отношении интерлейкина-6 (ил-6) человека
BRPI0516572A (pt) métodos e composições para melhorar a produção de proteìnas recombinantes
MX344592B (es) Metodo para eliminar extracorporalmente de la sangre un microbio patogeno, una celula inflamatoria o una proteina inflamatoria.
EP2826791A3 (fr) Anticorps anti-C5aR humanisés
WO2007025977A3 (fr) Nouveau traitement de l'enterocolite chronique
MX2009002388A (es) Uso de celulas humanas originarias de leucemia mieloide para la expresion de anticuerpos.
MX2010005966A (es) Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
DK3085783T3 (da) Bispecifikt antistof som substitution for funktionelle proteiner
WO2007056470A3 (fr) Antagonistes de la neuropiline
MA33717B1 (fr) Immunoconjugués ciblés
WO2006101387A3 (fr) STRUCTURE HYBRIDE ß COMPRENANT DES PROTEINES DE LIAISON AMYLOIDES ET METHODES DE DETECTION DE LA STRUCTURE HYBRIDE ß POUR MODULER LA FORMATION DE FIBRILLES DANS LES STRUCTURES HYBRIDES ß ET MODULER LA TOXICITE INDUITE PAR LA STRUCTURE HYBRIDE ß, ET PROCEDE VISANT A CONTRARIER LA COAGULATION SANGUINE
NO20091064L (no) Antistoffer mot IL-17A
EA201070553A1 (ru) Антитела к гепцидину и варианты их применения
UA96922C2 (en) Il-12/p40 binding protein
NZ595792A (en) Antibodies specific to cadherin-17
EP2631248A3 (fr) Traitement de tumeurs à l'aide d'un anticorps anti-L1 spécifique
WO2007067984A3 (fr) Anticorps neutralisants diriges contre le ligand psgl-1 de primate et utilisations a cet effet
EA201001762A1 (ru) Антитела и способы их получения
WO2006078648A3 (fr) Vaccins contre les rhinovirus
WO2006110496A3 (fr) Activation de la sodium potassium atpase
GB0620255D0 (en) Antibody and uses thereof
WO2004108065A3 (fr) Activite d'heparanase neutralisant un anticorps monoclonal anti-heparanase et d'autres anticorps anti-heparanase
EA200700425A1 (ru) Гликопротеин клеточной поверхности
MX338328B (es) Anticuerpo anti-ilt7.